EquityFlow
›
Companies
› Precirix
Precirix
Biotech
· Brussels, BE
Belgian biotech developing radio-immunotherapeutic drugs for cancer.
Funding history
Date
Round
Amount
Apr 2022
Series B
Brussels radiopharmaceutical biotech Precirix raised an 80M euro Series B co-led by INKEF Capital, Jeito Capital and Forbion.
$80M
Investors
Forbion
GIMV
HealthCap
INKEF Capital
Jeito Capital
Novo Holdings
Similar companies in Biotech
Imperagen
Haga Bioscience
Pixelgen Technologies
Gallant
Chai Discovery
SNIPR Biome
Cellbox Labs
Scope Biosciences
GenLumina
Actithera
NUCLIDIUM
Anocca
Explore funding flow on EquityFlow →